Products for Research Use Only

(S) -DMAPT

CAT: 0804-HY-16172ASize: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-16172ASize:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
(S) -DMAPT (Dimethylamino Parthenolide), an analogue of Parthenolide (PTL), is an oral active NF-κB inhibitor, with a LD50 of 1.7 μM for cell population in AML cells. Has potential anti-cancer and anti-metastatic effect[1].
CAS Number
870677-05-7
Product Name Alternative
(S) -Dimethylamino Parthenolide
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
NF-κB
Type
Reference compound
Related Pathways
NF-κB
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/s-dmapt.html
Solubility
10 mM in DMSO
Smiles
C[C@]12[C@@](O2)([H])[C@]3([H])[C@](CC/C(C)=C\CC1)([H])[C@H](C(O3)=O)CN(C)C
Molecular Formula
C17H27NO3
Molecular Weight
293.40
Precautions
H302, H315, H319, H335
References & Citations
[1]Neelakantan S, et al. Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1) . Bioorg Med Chem Lett. 2009 Aug 1;19 (15) :4346-9.|[2]Mendonca MS, et al. DMAPT inhibits NF-κB activity and increases sensitivity of prostate cancer cells to X-rays in vitro and in tumor xenografts in vivo. Free Radic Biol Med. 2017 Nov;112:318-326.|[3]Morel KL, et al. Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide. Clin Exp Metastasis. 2018 Oct;35 (7) :649-661.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported